Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LAVA-1207 |
| Synonyms | |
| Therapy Description |
LAVA-1207 is a bispecific gamma delta T-cell engager (TCE) antibody that targets prostate-specific membrane antigen (PSMA) expressed on tumor cells and Vdelta2 expressed on T-lymphocytes, which potentially leads to increased antitumor immune response and tumor cell killing (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LAVA-1207 | LAVA 1207|LAVA1207 | PSMA Antibody 22 | LAVA-1207 is a bispecific gamma delta T-cell engager (TCE) antibody that targets prostate-specific membrane antigen (PSMA) expressed on tumor cells and Vdelta2 expressed on T-lymphocytes, which potentially leads to increased antitumor immune response and tumor cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05369000 | Phase Ib/II | LAVA-1207 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer | Terminated | USA | NLD | ESP | 0 |